

SAFETY DATA SHEET

SECTION 1 – IDENTIFICATION

Product Identity: Chondroitinase B, recombinant in sucrose, Research grade
Part Number: 50-018

Manufacturer: IBEX Pharmaceuticals Inc.
5485 Rue Paré, Suite 100
Montréal, Québec, H4P 1P7 Canada
Tel : (514) 344-4004 Fax : (514) 344-8827

Product use: Research

SECTION 2 – HAZARD IDENTIFICATION

Emergency overview: Solution in water. Will not support burning. Not explosive.

Potential Health Effects:

Skin: May cause skin irritation
Eyes: May cause irritation or burning sensation
Inhalation: May cause irritation to the respiratory tract
Swallowed: Not known to cause toxic effects
Injection: Not known to cause toxicity with acute exposure, but may produce toxicity with repeated injections.

Carcinogenicity: Not determined

SECTION 3 – COMPOSITION/INFORMATION ON INGREDIENTS

CAS No.: 52227-83-5
EC No. 4.2.2.19

Systematic name: Chondroitin B lyase
Synonyms: Chondroitinase B

Origin: Recombinant, non-pathogenic microorganism

Ingredients: Recombinant protein in sodium phosphate; sodium chloride; sucrose; water

SECTION 4 – FIRST AID MEASURES

- Skin contact:** Flush with copious amounts of water.
Eye contact: Rinse opened eye for several minutes under running water. Then consult a doctor.
Inhalation: Supply the victim with fresh air; consult doctor in case of complaints.
Swallowing: Rinse mouth with plenty of water.
On all of the above: Consult a doctor if symptoms develop.

SECTION 5 – FIRE FIGHTING MEASURES

Suitable extinguishing agents: Noncombustible.

Protective equipment: No special measures required. Prevent contact with skin and eyes

SECTION 6 – ACCIDENTAL RELEASE MEASURES

Person-related safety precautions: Prevent contact with skin and eyes. Ventilate area.

Measures for environmental protection: No special measures required.

Measures for cleaning/collecting: Spilled material should be carefully wiped up and disposed as biomedical waste as per applicable waste disposal regulations. Wash spill site after material pickup is complete.

SECTION 7 – HANDLING AND STORAGE

Handling

Information for safe handling: Prevent contact with skin and eyes and prevent inhalation and swallowing. No other special precautions are necessary if used correctly.

Information about protection against explosions and fires: No special measures required.

Storage

Requirements to be met by storerooms and receptacles: No special requirements except that product should be stored frozen (preferably at -70 °C).

Information about storage in one common storage facility: Not required.

Further information about storage conditions: None

Storage class: None assigned

Class according to regulation on flammable liquids: Void

SECTION 8 – EXPOSURE CONTROLS / PERSONAL PROTECTION

General protective and hygienic measures: The usual precautionary measures for handling chemicals and potentially biohazardous materials should be followed. Use clothing sufficient to avoid skin contact. Safety shower and eye wash should be available in proximity.

Protection of hands: Use synthetic water resistant gloves.

Eye protection: Use safety glasses.

SECTION 9 – PHYSICAL AND CHEMICAL PROPERTIES

Physical form: Frozen, colorless, odorless aqueous solution.
(Chondroitinase B is a protein)

Melting point: 0 °C (melting point of aqueous solution)

Boiling point: Not applicable

Flash point: Not applicable

Flammability: Product is not flammable

Danger of explosion: Not determined

Solubility: Chondroitinase B and ingredients are water soluble

Organic solvents: 0 %

Solids content: 0 %

SECTION 10 – STABILITY AND REACTIVITY

Thermal decomposition / conditions to be avoided: No decomposition if used according to specifications.

Dangerous reactions: No dangerous reactions known.

Dangerous products of decomposition: No dangerous decomposition products known.

SECTION 11 – TOXICOLOGICAL INFORMATION

Effects of Acute Exposure: Low acute toxicity expected following inhalation, ingestion, injection or skin exposure.

The potential eye irritation effects of Chondroitinase B are unknown and it should be considered to be potentially irritating to the eyes.

Effects of Chronic Exposure: Not determined for oral ingestion or skin exposure.

Development Toxicity: Not determined

Reproductive Toxicity: Not determined

Carcinogenicity: Not determined

SECTION 12 – ECOLOGICAL INFORMATION

Toxicity: No data available
Persistence and degradability: No data available
Bioaccumulative potential: No data available
Mobility in soil: No data available
PBT and vPvB assessment: No data available
Other adverse effects: No data available

SECTION 13 – DISPOSAL INFORMATION

Waste Disposal:

Incinerate or bury as a solid in a licensed facility. Do not discharge into waterways or sewer systems without proper authority.

Container Disposal:

Dispose of in a licensed facility. Recommend crushing or other means to prevent unauthorized reuse.

SECTION 14 – TRANSPORT INFORMATION

DOT (US)

Not dangerous goods

IMDG

Not dangerous goods

IATA

Not dangerous goods

SECTION 15 – REGULATORY INFORMATION

Not a dangerous substance or mixture according to the Globally Harmonised System (GHS).

SECTION 16 – OTHER INFORMATION

Date of revision: March 10, 2016

This information is given without any warranty or representation. It is believed to be correct but does not claim to be all inclusive and shall be used only as a guide. IBEX Pharmaceuticals Inc. shall not be held liable for any damage resulting from handling or contact with the above product. It is offered solely for your consideration, investigation and verification.